SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer headquartered in Sydney, Australia, on December 7, 2016, with a report date of December 6, 2016. The filing serves to disclose specific corporate events rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of corporate actions and does not contain financial statements or performance metrics.
Material Changes and Corporate Actions
- New Issue Announcement: The filing includes Exhibit 99.1, which is an Appendix 3B regarding a new issue announcement.
- Director Interest Change: The filing includes Exhibit 99.2, which is an Appendix 3Y detailing a change in a Director's interest.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, specific risk factors, contingencies, or unusual items beyond the disclosed corporate actions.
Investor Verification Checklist
- Verify the terms and size of the new share issue referenced in Exhibit 99.1.
- Confirm the identity of the director and the nature of the interest change detailed in Exhibit 99.2.
- Review the full text of the attached exhibits for details not summarized in the cover page.